45 results found.

Advanced Cancers Clinical Trial using Lorazepam; Placebo; Haloperidol decanoate; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit.
Lorazepam; Placebo; Haloperidol decanoate; Questionnaires

Leukemia, or Neoplasms Clinical Trial using volasertib

Boehringer Ingelheim - Recruiting 2 years to 17 years.
- Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known.
volasertib

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit.
BI 836845

Carcinoma, or Lymphoma Clinical Trial using rh IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers.
rh IL-15

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Neoplasms Clinical Trial using MEHD7945A; cobimetinib

Genentech - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS.
MEHD7945A; cobimetinib

Solid Cancers Clinical Trial using paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors.
paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Solid Cancers Clinical Trial using Vismodegib

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function.
Vismodegib

Solid Cancers Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies.
MPDL3280A

Malignant Neoplasm Clinical Trial using fluorine F 18 d-FMAU; positron emission tomography; computed tomography

University of Southern California - Recruiting 19 years or older.
- 18F-FMAU for Imaging in Cancer Patients.
fluorine F 18 d-FMAU; positron emission tomography; computed tomography

Advanced Cancers Clinical Trial using Vandetanib; Everolimus

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer.
Vandetanib; Everolimus

Non Hematologic Cancers, Metastatic Cancer, or Lymphoma Clinical Trial using VS-5584

Verastem, Inc. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma.
VS-5584

Advanced Cancers Clinical Trial using Oxaliplatin; Capecitabine; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.
Oxaliplatin; Capecitabine; Bevacizumab

Advanced Lung Cancer Clinical Trial using Ganetespib (STA-9090) and crizotinib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers.
Ganetespib (STA-9090) and crizotinib

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Thyroid Neoplasm Clinical Trial using Valproic Acid

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin.
Valproic Acid

Advanced Cancers Clinical Trial using Crizotinib (Xalkori); Pazopanib; Pemetrexed

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies.
Crizotinib (Xalkori); Pazopanib; Pemetrexed

Advanced Cancers Clinical Trial using Everolimus; Anakinra; Denosumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies.
Everolimus; Anakinra; Denosumab

Advanced Cancers, DLBCL, or Lymphoma Clinical Trial using ISIS-STAT3Rx

Isis Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers.
ISIS-STAT3Rx

Advanced Cancers Clinical Trial using Telephone Survey

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer.
Telephone Survey

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Advanced Cancers Clinical Trial using Hydroxychloroquine; Sirolimus; Vorinostat

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies.
Hydroxychloroquine; Sirolimus; Vorinostat

Carcinoma, Non-small Cell Lung Clinical Trial using Dasatinib

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation.
Dasatinib

Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourin Clinical Trial using IGF-Methotrexate

University of Illinois at Chicago - Recruiting 18 years or older.
- STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R.
IGF-Methotrexate

Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squam Clinical Trial using OPB-111001

Otsuka Novel Products GmbH - Recruiting 18 years or older.
- A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment.
OPB-111001

Advanced Cancers Clinical Trial using Litebook; Melatonin; Methylphenidate; Placebo; Counseling Sessions; Questionnaires; Study Diaries

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer.
Litebook; Melatonin; Methylphenidate; Placebo; Counseling Sessions; Questionnaires; Study Diaries

Gastrointestinal Cancers Clinical Trial using Capecitabine; Oxaliplatin; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater.
Capecitabine; Oxaliplatin; Bevacizumab

Advanced Cancers Clinical Trial using Temsirolimus; Metformin

M.D. Anderson Cancer Center - Recruiting 14 years or older.
- Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers.
Temsirolimus; Metformin

Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers.
6,8-bis(benzylthio)octanoic acid

Liver Cancer, or Advanced Cancer Clinical Trial using Irinotecan; Bevacizumab; Oxaliplatin; Cetuximab

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver.
Irinotecan; Bevacizumab; Oxaliplatin; Cetuximab

Neoplasm Metastasis Clinical Trial using LY2940680

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors.
LY2940680

Cancer Clinical Trial using Trametinib (single tablet); Trametinib (Multiple tablet)

GlaxoSmithKline - Recruiting 20 years to 80 years.
- A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers.
Trametinib (single tablet); Trametinib (Multiple tablet)

Patients With Advanced Gastric or Pancreatic Cancers Clinical Trial using Early best palliative care

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori - Recruiting 18 years or older.
- The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial..
Early best palliative care

Advanced Cancers Clinical Trial using Vemurafenib; Cetuximab; Irinotecan

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies.
Vemurafenib; Cetuximab; Irinotecan

Advanced Cancer Clinical Trial using Vintafolide; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers.
Vintafolide; Carboplatin; Paclitaxel

Lung Cancer, or Solid Tumor (Not Breast or Prostate Cancers) Clinical Trial using Cabozantinib

Massachusetts General Hospital - Recruiting 18 years or older.
- Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases.
Cabozantinib

Dehydration, or Advanced Cancers Clinical Trial using Survey

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Physician Perceptions About Parenteral Hydration in Latin America and Spain: A Survey of Physicians Affiliated With the Latin American Association for Palliative Care (ALCP) and the Spanish Society for Palliative Care (SECPAL).
Survey

Advanced Cancers, or Solid Tumors Clinical Trial using Erlotinib; Pralatrexate

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer.
Erlotinib; Pralatrexate

Advanced Cancers Clinical Trial using Vemurafenib; Sorafenib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Vemurafenib (BRAF Inhibitor) and Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) in Patients With Advanced Malignancies.
Vemurafenib; Sorafenib

Advanced Cancers, or Lymphoma Clinical Trial using NC-4016

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma.
NC-4016

Head and Neck Cancer, or Head and Neck Squamous Cell Carcinoma Clinical Trial using Cyclophosphamide; Cetuximab

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Potentiation of Cetuximab by Tregs Depletion With Metronomic Cyclophosphamide in Metastatic Squamous Cell Cancers of Head and Neck.
Cyclophosphamide; Cetuximab

Advanced Cancers (Solid Tumors) Clinical Trial using GL-ONC1

Genelux Corporation - Recruiting 18 years or older.
- Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers..
GL-ONC1

Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Gen Clinical Trial

University Health Network, Toronto - Recruiting 18 years or older.
- Integrated Molecular Profiling in Advanced Cancers Trial.

Advanced Cancer, or Metastatic Cancer Clinical Trial using Tanibirumab

PharmAbcine - Recruiting 20 years or older.
- A Phase I Study of the Safety and Pharmacokinetics of a Fully Human Monoclonal Antibody to the Vascular Endothelial Growth Factor Receptor2 (Tanibirumab) in Patients With Advanced Cancers or Metastatic Cancer.
Tanibirumab

Head and Neck Cancer Clinical Trial using ABI-007

University Health Network, Toronto - Recruiting 18 years or older.
- Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC).
ABI-007